Last reviewed · How we verify

NCT06784154: BHIVA

The Role of Ectopic Fat and Heart Attack Risk in HIV

Recruiting now Last updated 19 February 2026
What this trial tests

trial testing Non-interventional in Cardiometabolic Syndrome in 100 participants. Currently enrolling.

Timeline
1 August 2024
Primary endpoint
30 June 2027
30 June 2027

Quick facts

Lead sponsorUniversity of Liverpool
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment100
Start date1 August 2024
Primary completion30 June 2027
Estimated completion30 June 2027
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

University of Liverpool

Who can join

40 and older, any sex, with Cardiometabolic Syndrome or Hiv. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to investigate differences between people living with HIV (PLWHIV) and general populations on how the body utilises and stores energy. This study uses magnetic resonance imaging (MRI) to measure fat around the body organs including the heart and liver. The fat around body organs, also known as visceral fat, is known to be associated with metabolic syndrome and a risk factor for developing heart attacks and strokes. MRI scans are used frequently in hospitals to diagnose a range of conditions. These scans use radio waves to measure protons in body tissues. The machines can reconstruct tissues using complex algorithms to form composite images of body structures. MRI scans do not use ionising radiation and there is no risk to undertaking an MRI in terms of radiation. We often use MRI scans to assess the hearts' structure and function. In addition, we can use specific MRI sequences to assess the integrity of heart muscle. Heart MRI is often considered the gold standard imaging technique to assess the heart and heart muscle disease. This sub-study will use multiple MRI sequences to assess the heart and the liver. We are aiming to investigate any changes in heart and liver fat. In addition, we will assess any changes in fat levels within the heart muscle cells whilst also assessing for any change in the way the heart is functioning. PLWHIV have roughly double the risk of heart attacks compared to general populations. Previous studies have demonstrated that this increased risk may arise from the way in which fat is stored and metabolised in the body. We hope this study will give insight into why HIV-positive individuals have increased risks of heart attacks and how reducing visceral fat may reduce risk. It may lead to further medicines or treatment strategies to reduce the risk of heart attacks in HIV-positive individuals.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Non-interventional

Trials testing the same drug.

Other recruiting trials for Cardiometabolic Syndrome

Currently open trials in the same condition.

Other University of Liverpool trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06784154.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing